Microbot Medical Inc. (NASDAQ:MBOT) Receives Average Rating of "Hold" from Analysts

Key Points

• Analyst consensus is “Hold”: Of five analysts covering Microbot Medical, three recommend buying, one recommends holding, and one recommends selling. The average 12-month price target is $6.375.
• Shares remain near their 52-week low: MBOT opened at $1.48, compared with a 52-week range of $1.44 to $4.67, and trades below both its 50-day and 200-day moving averages.
• Quarterly results met expectations: The company reported a loss of $0.08 per share, in line with estimates, while revenue of $0.24 million exceeded the $0.13 million consensus forecast.

Microbot Medical Inc. (NASDAQ:MBOT - Get Free Report) has been given an average rating of "Hold" by the five analysts that are covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and three have assigned a buy recommendation to the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $6.3750.

A number of brokerages have issued reports on MBOT. Wall Street Zen upgraded Microbot Medical from a "strong sell" rating to a "sell" rating in a research report on Saturday, May 16th. B. Riley Financial reissued a "buy" rating and set a $4.00 price target (down from $5.00) on shares of Microbot Medical in a report on Friday, August 14th. Zacks Research cut shares of Microbot Medical from a "strong-buy" rating to a "hold" rating in a research note on Thursday, August 20th. Loop Capital set a $4.00 price objective on shares of Microbot Medical in a report on Wednesday, June 3rd. Finally, HC Wainwright reiterated a "buy" rating on shares of Microbot Medical in a research report on Wednesday, August 19th.

Microbot Medical Trading Down 1.3%

Shares of NASDAQ:MBOT opened at $1.48 on Friday. The firm's 50 day moving average is $1.74 and its two-hundred day moving average is $2.04. Microbot Medical has a 52 week low of $1.44 and a 52 week high of $4.67. The firm has a market capitalization of $99.41 million, a P/E ratio of -6.17 and a beta of 1.06.

Microbot Medical (NASDAQ:MBOT - Get Free Report) last issued its quarterly earnings data on Tuesday, August 11th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.08). The business had revenue of $0.24 million for the quarter, compared to analyst estimates of $0.13 million. Analysts predict that Microbot Medical will post -0.31 EPS for the current year.

Institutional Trading of Microbot Medical

A number of institutional investors have recently made changes to their positions in the stock. Zacks Investment Management bought a new position in shares of Microbot Medical in the third quarter valued at approximately $33,000. CTC Alternative Strategies Ltd. bought a new stake in Microbot Medical during the first quarter worth approximately $28,000. Squarepoint Ops LLC bought a new stake in Microbot Medical during the third quarter worth approximately $37,000. American Century Companies Inc. acquired a new stake in Microbot Medical in the second quarter worth approximately $32,000. Finally, Wexford Capital LP acquired a new stake in Microbot Medical in the third quarter worth approximately $50,000. 16.30% of the stock is owned by institutional investors and hedge funds.

About Microbot Medical

Microbot Medical Inc NASDAQ: MBOT is a medical device company focused on the design, development and commercialization of micro-robotic platforms for minimally invasive procedures. Leveraging proprietary microbot technology, the company aims to navigate complex vascular and luminal pathways within the body to deliver therapy, retrieve tissue samples or perform diagnostic tasks in a precise, targeted manner.

Microbot Medical operates two primary technology divisions. Its endovascular platform is designed to traverse blood vessels and deliver clot-retrieval systems, drug payloads or cell-based therapies directly at the site of vascular injury, with applications in acute ischemic stroke and peripheral artery disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source